Oxandrolone Topics

• savient pharmaceuticals inc
• body surface area
• bio technology general corporation
• hereditary angioedema
• double blind study
• bad publicity
• total body surface area
• body composition
• oxandrin
• burn care
• study patients
• ldl
• searle
• laboratory tests
• muscle mass
• heart disease
• bodybuilders
• osteoporosis
• clinical trials

Related Images

Source

del.icio.us Tags

• aids
• medication
• hiv
• wasting
• antiwasting
• testosterone

Oxandrolone, Oxandrolone

It had also been shown to be partially successful in treating cases of osteoporosis. However, in part due to bad publicity from its abuses by bodybuilders, Oxandrolone was discontinued by Searle Laboratories in 1989. It was picked up by Bio-Technology General Corporation, now Savient Pharmaceuticals, Inc. who, following successful clinical trials in 1995, released it under the tradename Oxandrin.

In addition, the drug has shown positive results in treating anaemia and hereditary angioedema.In a randomized, double-blind study, patients with 40% total body surface area burns were selected to receive standard burn care plus Oxandrolone, or without Oxandrolone. Those treated with Oxandrolone showed improve body composition, preserved muscle mass and reduced hospital stay time.

This may increase the risk of developing heart disease. Oxandrolone may damage the liver or increase LDL without causing symptoms. It is important to have regular laboratory tests to be sure that the liver is working properly and that LDL has not increased. Oxandrolone may also decrease fertility in men.

Source: Wikipedia > Oxandrolone